

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

[Search for additional matches among the next 2000 terms](#)

Search Results -

Term	Documents
B7.DWPI,EPAB,JPAB,USPT,PGPB.	8654
B7S	0
METHOD.DWPI,EPAB,JPAB,USPT,PGPB.	4848553
METHODS.DWPI,EPAB,JPAB,USPT,PGPB.	1002899
INHIBIT\$	0
INHIBIT.DWPI,EPAB,JPAB,USPT,PGPB.	265581
INHIBITA.DWPI,EPAB,JPAB,USPT,PGPB.	2
INHIBITABILITIES.DWPI,EPAB,JPAB,USPT,PGPB.	1
INHIBITABILITY.DWPI,EPAB,JPAB,USPT,PGPB.	62
INHIBITABLE.DWPI,EPAB,JPAB,USPT,PGPB.	660
.....	
BLOCK\$(BLOCKS-DETAILS).USPT,PGPB,JPAB,EPAB,DWPI.	pickup term
((B7) SAME (METHOD) SAME (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR ADMINIST\$)).USPT,PGPB,JPAB,EPAB,DWPI.	164

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

(B7) same (method) same (inhibit\$ or
suppress\$ or block\$ or prevent\$ or
administ\$)

[Clear](#)**Search History**

Today's Date: 9/9/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	(B7) same (method) same (inhibit\$ or suppress\$ or block\$ or prevent\$ or administ\$)	164	<u>L5</u>
USPT,PGPB	(B7) same (method).clm.	34	<u>L4</u>
USPT,PGPB	(B7).clm.	243	<u>L3</u>
USPT,PGPB	linsley-peter\$ and B7	19	<u>L2</u>
USPT,PGPB	linsley-peter\$	38	<u>L1</u>

WEST

Generate Collection

Search Results - Record(s) 1 through 10 of 19 returned.☐ 1. Document ID: US 6183734 B1

L2: Entry 1 of 19

File: USPT

Feb 6, 2001

US-PAT-NO: 6183734

DOCUMENT-IDENTIFIER: US 6183734 B1

TITLE: Inhibition of tumor cell growth by administration of B7-transfected cells

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chen; Lieping	Seattle	WA	N/A	N/A
Hellstrom; Ingegerd	Seattle	WA	N/A	N/A
Hellstrom; Karl Erik	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/93.21; 424/277.1, 424/278.1, 424/93.7, 435/325

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 6132992 A

L2: Entry 2 of 19

File: USPT

Oct 17, 2000

US-PAT-NO: 6132992

DOCUMENT-IDENTIFIER: US 6132992 A

TITLE: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Seattle	WA	N/A	N/A
Hayden; Martha S.	San Diego	CA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Bajorath; Jurgen	Everett	WA	N/A	N/A
Fell; H. Perry	Redmond	WA	N/A	N/A

US-CL-CURRENT: 435/69.7; 435/320.1, 435/326, 435/328, 530/387.3, 530/387.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 3. Document ID: US 6090914 A

L2: Entry 3 of 19

File: USPT

Jul 18, 2000

US-PAT-NO: 6090914

DOCUMENT-IDENTIFIER: US 6090914 A

TITLE: CTLA4/CD28Ig hybrid fusion proteins and uses thereof

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Bajorath; Jurgen	Lynnwood	WA	N/A	N/A
Peach; Robert	Edmonds	WA	N/A	N/A
Brady; William	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 530/350; 424/192.1, 435/69.7, 530/387.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 4. Document ID: US 5993800 A

L2: Entry 4 of 19

File: USPT

Nov 30, 1999

US-PAT-NO: 5993800

DOCUMENT-IDENTIFIER: US 5993800 A

TITLE: Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Kay; Mark A.	Seattle	WA	N/A	N/A
Wilson; Christopher B.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey	Seattle	WA	N/A	N/A
Aruffo; Alejandro A.	Seattle	WA	N/A	N/A
Hollenbaugh; Diane L.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/93.21; 424/93.1, 435/320.1, 435/325, 435/69.1, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 5. Document ID: US 5977318 A

L2: Entry 5 of 19

File: USPT

Nov 2, 1999

US-PAT-NO: 5977318

DOCUMENT-IDENTIFIER: US 5977318 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 530/388.1; 424/141.1, 424/143.1, 435/331, 435/334, 530/388.15,
530/388.73, 530/861, 530/866, 530/868

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 6. Document ID: US 5968510 A

L2: Entry 6 of 19

File: USPT

Oct 19, 1999

US-PAT-NO: 5968510

DOCUMENT-IDENTIFIER: US 5968510 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 424/141.1; 424/139.1, 424/143.1, 424/154.1, 424/809, 424/810,
514/12, 514/2, 530/388.1, 530/388.15, 530/388.22, 530/388.73

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 7. Document ID: US 5916560 A

L2: Entry 7 of 19

File: USPT

Jun 29, 1999

US-PAT-NO: 5916560
DOCUMENT-IDENTIFIER: US 5916560 A

TITLE: Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith

DATE-ISSUED: June 29, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larsen; Christian P.	Atlanta	GA	N/A	N/A
Aruffo; Alejandro A.	Edmonds	WA	N/A	N/A
Hollenbaugh; Diane L.	Seattle	WA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Pearson; Thomas C.	Atlanta	GA	N/A	N/A

US-CL-CURRENT: 424/154.1; 424/130.1, 424/139.1, 424/143.1, 424/153.1,
424/173.1, 514/2, 514/8, 530/387.3, 530/388.73, 530/388.75

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 8. Document ID: US 5885796 A

L2: Entry 8 of 19

File: USPT

Mar 23, 1999

US-PAT-NO: 5885796
DOCUMENT-IDENTIFIER: US 5885796 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.1, 536/23.4,
536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 9. Document ID: US 5885579 A

L2: Entry 9 of 19

File: USPT

Mar 23, 1999

US-PAT-NO: 5885579

DOCUMENT-IDENTIFIER: US 5885579 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 424/192.1; 424/133.1, 424/141.1, 435/69.1, 435/69.7, 435/7.2,
514/12, 514/2, 530/350, 530/387.1, 530/866, 530/868

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 10. Document ID: US 5851795 A

L2: Entry 10 of 19

File: USPT

Dec 22, 1998

US-PAT-NO: 5851795

DOCUMENT-IDENTIFIER: US 5851795 A

TITLE: Soluble CTLA4 molecules and uses thereof

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/69.7, 530/350,
530/367, 530/387.3, 536/23.1, 536/23.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

[Generate Collection](#)

Term	Documents
LINSLEY-PETER\$	0
LINSLEY-PETER.USPT,PGPB.	7
LINSLEY-PETER-S.USPT,PGPB.	31
B7.USPT,PGPB.	7269
B7S	0
(LINSLEY-PETER\$ AND B7).USPT,PGPB.	19

Documents, starting with Document:

Display Format:

WEST

Generate Collection

Search Results - Record(s) 11 through 19 of 19 returned.☐ 11. Document ID: US 5844095 A

L2: Entry 11 of 19

File: USPT

Dec 1, 1998

US-PAT-NO: 5844095

DOCUMENT-IDENTIFIER: US 5844095 A

TITLE: CTLA4 Ig fusion proteins

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 530/387.3; 424/134.1, 424/192.1, 435/69.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 12. Document ID: US 5807734 A

L2: Entry 12 of 19

File: USPT

Sep 15, 1998

US-PAT-NO: 5807734

DOCUMENT-IDENTIFIER: US 5807734 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Diegel; Michael L.	Kent	WA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Seattle	WA	N/A	N/A
Moran; Patricia A.	Seattle	WA	N/A	N/A
Zarling; Joyce M.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/252.33; 424/134.1, 424/135.1, 424/192.1, 435/320.1,
435/70.21, 514/44, 530/387.3, 530/388.22, 536/23.53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 13. Document ID: US 5795572 A

L2: Entry 13 of 19

File: USPT

Aug 18, 1998

US-PAT-NO: 5795572

DOCUMENT-IDENTIFIER: US 5795572 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Diegel; Michael L.	Kent	WA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Seattle	WA	N/A	N/A
Moran; Patricia A.	Seattle	WA	N/A	N/A
Zarling; Joyce M.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/135.1, 424/133.1, 424/141.1, 424/143.1, 424/154.1,
424/156.1, 424/178.1, 530/387.3, 530/388.1, 530/388.22, 530/391.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 14. Document ID: US 5773253 A

L2: Entry 14 of 19

File: USPT

Jun 30, 1998

US-PAT-NO: 5773253

DOCUMENT-IDENTIFIER: US 5773253 A

TITLE: MYPPPY variants of CTL A4 and uses thereof

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Peach; Robert	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 435/69.7, 435/252.3, 435/320.1, 435/358, 435/361, 435/362,
435/69.1, 530/350, 530/387.1, 530/387.3, 530/388.75, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 15. Document ID: US 5770197 A

L2: Entry 15 of 19

File: USPT

Jun 23, 1998

US-PAT-NO: 5770197

DOCUMENT-IDENTIFIER: US 5770197 A

TITLE: Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Renton	WA	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Wallace; Philip M.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/134.1; 424/139.1, 424/144.1, 424/192.1, 424/810, 435/69.7, 530/350, 530/388.7, 530/868

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 16. Document ID: US 5637481 A

L2: Entry 16 of 19

File: USPT

Jun 10, 1997

US-PAT-NO: 5637481

DOCUMENT-IDENTIFIER: US 5637481 A

TITLE: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

DATE-ISSUED: June 10, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Seattle	WA	N/A	N/A
Hayden; Martha S.	San Diego	CA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Bajorath; Jurgen	Everett	WA	N/A	N/A
Fell; H. Perry	Redmond	WA	N/A	N/A

US-CL-CURRENT: 435/69.6; 435/320.1, 435/325, 435/326, 435/328, 435/332, 435/365, 435/69.1, 435/69.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 17. Document ID: US 5580756 A

L2: Entry 17 of 19

File: USPT

Dec 3, 1996

US-PAT-NO: 5580756
DOCUMENT-IDENTIFIER: US 5580756 A

TITLE: B7IG fusion protein

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Renton	WA	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 435/69.7; 435/91.1, 530/350, 530/387.1, 530/387.3, 530/395,
536/23.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 18. Document ID: US 5521288 A

L2: Entry 18 of 19

File: USPT

May 28, 1996

US-PAT-NO: 5521288
DOCUMENT-IDENTIFIER: US 5521288 A

TITLE: CD28IG fusion protein

DATE-ISSUED: May 28, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Renton	WA	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 530/387.3; 435/252.3, 435/252.33, 435/320.1, 435/69.1, 435/69.7,
435/7.2, 435/7.92, 435/91.1, 530/300, 530/350, 530/387.1, 530/395, 530/409,
530/866, 530/867, 530/868, 536/23.1, 536/23.4, 536/23.53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 19. Document ID: US 5434131 A

L2: Entry 19 of 19

File: USPT

Jul 18, 1995

US-PAT-NO: 5434131

DOCUMENT-IDENTIFIER: US 5434131 A

TITLE: Chimeric CTLA4 receptor and methods for its use

DATE-ISSUED: July 18, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Renton	WA	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 514/2; 424/133.1, 514/12, 530/350, 530/866, 530/868

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KNOWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-------	-----------	-------

[Generate Collection](#)

Term	Documents
LINSLEY-PETER\$	0
LINSLEY-PETER.USPT,PGPB.	7
LINSLEY-PETER-S.USPT,PGPB.	31
B7.USPT,PGPB.	7269
B7S	0
(LINSLEY-PETER\$ AND B7).USPT,PGPB.	19

[Display](#)[10](#)

Documents, starting with Document:

[19](#)**Display Format:**[CIT](#)[Change Format](#)

2/7/23 (Item 23 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11848686 BIOSIS NO.: 199900094795

Targeting of A **B7-1** (CD80) immunoglobulin G1 (IgG) **fusion protein** to acute myeloid leukemia (AML) blasts increases their costimulatory activity for autologous remission T cells.

AUTHOR: Willinger T; Thiel E; Notter M

AUTHOR ADDRESS: Dep. Hematol. Oncol., Lab. Applied Cell. Mol. Immunol.,
Universitaetsklin. Benjamin Franklin, FU Ber**Germany

JOURNAL: Annals of Hematology 77 (SUPPL. 2):pS112 1998

CONFERENCE/MEETING: Annual Congress of the German and Austrian Societies of
Hematology and Oncology Frankfurt, Germany October 25-28, 1998

SPONSOR: Austrian Society of Hematology and Oncology

ISSN: 0939-5555

RECORD TYPE: Citation

2/7/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11876379 BIOSIS NO.: 199900122488
Systemic treatment with **soluble B7**-IgG fusion proteins
significantly prolongs the survival of leukemic mice.
AUTHOR: Dunussi-Joannopoulos K; Runyon K; Sturmhoefel K; Schaub R G;
Leonard J P
AUTHOR ADDRESS: Genet. Inst. Inc., Andover, MA**USA
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p617A Nov. 15, 1998
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of
Hematology Miami Beach, Florida, USA December 4-8, 1998
SPONSOR: The American Society of Heamatology
ISSN: 0006-4971
RECORD TYPE: Citation

2/7/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12028015 BIOSIS NO.: 199900308534

Induction of therapeutic T-cell immunity by **tumor** targeting with
soluble recombinant **B7**-immunoglobulin costimulatory
molecules.

AUTHOR: Moro Monica; Gasparri Anna Maria; Pagano Stefano; Bellone Matteo;
Tornaghi Paola; Veglia Fabrizio; Corti Angelo; Casorati Giulia; Dellabona
Paolo(a)

AUTHOR ADDRESS: (a)Unita d'Immunochimica, DIBIT, Istituto Scientifico San
Raffaele, Via Olgettina 58, Milan, 20132**Italy

JOURNAL: Cancer Research 59 (11):p2650-2656 June 1, 1999

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: **Tumor** targeting with immunomodulatory molecules is an attractive strategy to enhance the host's antitumor response. Expression of CD80 (B7-1) and CD86 (B7-2) costimulatory molecules in **tumor** cells has proven to be an efficient way to enhance their immunogenicity. Here, we studied the effects of **tumor** targeting with biotinylated recombinant **soluble B7-1**- and **B7-2** immunoglobulin G molecules (bio-**B7**-IgG) using a pretargeting approach based on the sequential use of a biotinylated antitumor monoclonal antibody and avidin. Mouse RMA T-lymphoma cells bearing either bio-B7-1-IgG or bio-B7-2-IgG on their surface prime in vitro naive CD8+ CTLs, which are highly effective in adoptive immunotherapy, and induce therapeutic immunity when injected in **tumor**-bearing animals. In vivo targeting of established RMA **tumors** with bio-B7-IgG either cures **tumor**-bearing mice or significantly prolongs their survival. The antitumor response induced by targeted bio-B7-IgG depends on both CD4+ and CD8+ T cells. Moreover, **tumor** targeting with bio-B7-IgG in vivo is critical for both expansion in lymphoid organs and mobilization into the **tumor** of **tumor**-specific CD8+ CTLs. When targeting is performed on poorly immunogenic TS/A mammary adenocarcinoma, only bio-B7-1-IgG primes naive CTLs in vitro and cures or significantly prolongs the survival of **tumor**-bearing mice in vivo, confirming that the two costimulatory molecules are not redundant with this **tumor**. Altogether, these data suggest that **tumor** avidination and targeting with **soluble** bio-**B7**-IgG may represent a

Set	Items	Description
S1	138	(B7?)(20N)(SOLUBLE OR FUSION(W)PROTEIN) AND (TUMOR? OR TUM- OUR? OR CANCER? OR NEOPLAS?)
S2	75	RD S1 (unique items)
		? s (B7?)(20n)(soluble or fusion(w)protein) and (autoimmun? or vivo or transplant? or graft?)

```

18476 B7?
343737 SOLUBLE
328213 FUSION
3893136 PROTEIN
43418 FUSION(W) PROTEIN
648 B7?(20N) (SOLUBLE OR FUSION(W) PROTEIN)
176215 AUTOIMMUN?
942633 VIVO
1267038 TRANSPLANT?
456618 GRAFT?
S3 382 (B7?) (20N) (SOLUBLE OR FUSION(W) PROTEIN) AND (AUTOIMMUN?
OR VIVO OR TRANSPLANT? OR GRAFT?)

```

382 S3
2984937 REVIEW?
S4 13 S3 AND REVIEW?

```
...completed examining records
      S5      7  RD S4 (unique items)
? t s5/7/all
```

09952450 BIOSIS NO.: 199598407368
Steroids as regulators of the mammalian immune response.
AUTHOR: Daynes Raymond A(a); Araneo Barbara A; Hennebold Jon; Enioutina
Elena; Mu Hong Hua
AUTHOR ADDRESS: (a)Dep. Pathol., Univ. Utah Sch. Med., Salt Lake City, UT
84132**USA
JOURNAL: Journal of Investigative Dermatology 105 (1 SUPPL.):p14S-19S 1995
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The mammalian immune system is multicellular in composition, and its proper function requires careful control over complex developmental pathways and many distinct types of effector responses. Numerous overlapping mechanisms of intercellular communication are needed to accomplish the tasks of proper regulation of the diverse cell types that constitute this essential protective system. One mechanism occurs by direct cell-to-cell contact through the interaction of membrane-associated molecules. Examples of this type of communication include the interaction that takes place between the antigen-specific

T-cell receptor and the foreign peptides that are bound to major histocompatibility complex molecules, as well as costimulatory molecule interactions with their specific ligands expressed on antigen-presenting cells (e.g., CD28 and B7-1 or B7-2). A second mechanism occurs through the production, secretion, and activities of **soluble** mediators, collectively known as the cytokines. The cytokines are represented by a large and diverse group of molecules that are produced by a wide variety of cell types. Unique species of cytokines bind to specific membrane-associated receptors on target cells, inducing the activation of particular signal-transduction pathways. These processes subsequently lead to the diversity of cytokine-linked changes in cellular physiology. Some of the cytokines exert their influences **in vivo** via endocrine routes, although it is far more common for intercellular communication via cytokines to occur microenvironmentally via paracrine or autocrine pathways. The object of this **review** is to provide evidence supporting the concept that one mechanism for upstream regulation of cytokine production by immunocompetent cell types is controlled by the regulatory activities of various steroid hormones. Strain variation in susceptibility to infectious agents, the condition of immunosenescence, and the processes that control the development of common mucosal immunity are used as examples of immune mechanisms that may be under steroid hormone control.

5/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09783333 BIOSIS NO.: 199598238251
Immunotherapy of multiple myeloma.
AUTHOR: Huang Yi-Wu; Vitetta Ellen S(a)
AUTHOR ADDRESS: (a)Univ. Texas Southwestern Med. Cent., Cancer Immunobiol.
Cent., 6000 Harry Hines Blvd., NB9 210, **USA
JOURNAL: Stem Cells (Dayton) 13 (2):p123-134 1995
ISSN: 1066-5099
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This **review** focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow **transplantation** using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in **vivo** with anti-CD3 and IL-2, as well as **transplantation** of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant **soluble** gp130, anti-B7, antiHLA-DR, and recombinant **soluble** CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.

5/7/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06417456 EMBASE No: 1996080901

Costimulation and its role in organ **transplantation**

Bluestone J.A.

Ben May Institute, University of Chicago, 5841 South Maryland

Avenue, Chicago, IL-60637-1470 United States

Clinical Transplantation (CLIN. TRANSPLANT.) (Denmark) 1996, 10/1 II
(104-109)

CODEN: CLTRE ISSN: 0902-0063

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Antigen-specific T-cell activation depends initially on the interaction of the T-cell receptor with peptide/major histocompatibility complex (MHC). In addition, a costimulatory signal, mediated by distinct cell surface accessory molecules such as CD28, is required for complete T-cell activation. One essential element of the CD28 costimulatory system that makes it an attractive target for immunotherapy is the selective effect of CD28 antagonists on activated T cells. Only cells encountering antigen presenting cells (APCs) without the appropriate CD28 ligand will be rendered functionally inactive as desired for any next-generation immunosuppressive drug. This brief **review** will focus on the role of CD28/B7 interactions in regulating organ **graft** rejection. In vitro and in **vivo** studies will describe the use of a **soluble fusion protein** antagonist of CD28/B7 (CTLA-4Ig), anti-B7 MAbs, and genetically altered CD28 'knockout' mice to study immune responses. The studies suggest that: 1) CTLA-4Ig induces long term, antigen specific unresponsiveness in **vivo**; 2) two distinct ligands for CD28, B7-1 and B7-2, are differentially regulated during immune responses; and 3) both B7-1 and B7-2 costimulatory molecules are active, in **vivo**, although B7-2 plays a clearly dominant role in murine allograft rejection.

5/7/4 (Item 2 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

06361238 EMBASE No: 1996025020

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis

Perrin P.J.; Scott D.; June C.H.; Racke M.K.

Immune Cell Biology Program, Naval Medical Research Institute, Mail Stop

06, Bethesda, MD 20889-5607 United States

Immunologic Research (IMMUNOL. RES.) (Switzerland) 1995, 14/3
(189-199)

CODEN: IMRSE ISSN: 0257-277X

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

T-cell activation requires signalling provided by ligation of the T-cell receptor for antigen (TCR) and a second antigen (Ag) nonspecific signal, known as costimulation. The B7 receptors, CD80 (B7-1) and CD86 (B7-2), on the Ag-presenting cell (APC), interact with T-cell CD28 or CTLA-4 to deliver a costimulatory signal, which is particularly important for Th1 activation. Experimental allergic encephalomyelitis (EAE) is an **autoimmune** disorder, induced by Th1 cells directed against myelin antigens that provides an in **vivo** model for studying the role of B7-mediated costimulation in the induction of a pathological immune response. Using a **soluble fusion protein** ligand for the B7 receptors, as well as specific monoclonal antibodies specific for either CD80 or CD86, it has been demonstrated that B7 costimulation plays a prominent role in determining clinical disease outcome in EAE. Here we **review** recent data indicating that a paradoxical exacerbation of disease as well as the expected amelioration of disease can occur with costimulatory receptor blockade.

5/7/5 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06234052 EMBASE No: 1995252008
Blocking CD28/B7 with **soluble** competitors: Immunological
phenotype of mCTLA4-Hgammal transgenic mice
Lane P.
Basel Institute for Immunology, Grenzacherstrasse 487, Basel CH-4005
Switzerland
Research in Immunology (RES. IMMUNOL.) (France) 1995, 146/3 (176-179)
CODEN: RIMME ISSN: 0923-2494
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH

5/7/6 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06008923 EMBASE No: 1995037578
Immunomodulation of **transplant** rejection using monoclonal
antibodies and soluble receptors
Alegre M.-L.; Lenschow D.J.; Bluestone J.A.
Department of Pathology, University of Chicago, Chicago, IL 60637 United
States
Digestive Diseases and Sciences (DIG. DIS. SCI.) (United States) 1995
40/1 (58-64)
CODEN: DDSCD ISSN: 0163-2116
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The main objective of our studies has been to optimize the effects of monoclonal antibodies (MAbs) and other immunosuppressive reagents to enhance organ **graft** survival. One such agent is OKT3, a MAb that is directed against the CD3 component of the human T-cell receptor (TCR) complex. Treatment of a rejection episode with OKT3 results in a rapid and efficient clearing of circulating T cells and reversal of most rejection episodes. Its wider use in **transplantation** and in the treatment of immune-mediated disease is limited by adverse reactions that follow the initial dose, the production of neutralizing Abs, and the transient nature of the immunosuppression. We have engineered CDR-**grafted** 'humanized' anti-CD3 MAbs that lack Fc-receptor binding activity through mutagenesis of amino acids in the Fc portion of the MAb. This results in an immunosuppressive anti-CD3 MAb that is less antigenic and one that does not induce the first-dose side effects. In addition, we have pursued a goal of developing a therapy that will induce donor-specific tolerance while maintaining overall recipient immune competency. Because antigen-specific T-cell activation depends not only on TCR-ligand interaction, but also on additional costimulatory signals mediated by accessory molecules such as CD28, blocking the binding of CD28 on T cells to its-ligand **B7**, during TCR engagement, might modulate **transplantation** responses. Using a **soluble fusion protein** of human CTLA4, CTLA4-Ig, that binds **B7** with high affinity, inhibition of human pancreatic islet rejection that occurs, at least in part, by affecting T-cell recognition of human B7sup + antigen-presenting cells has been demonstrated. In addition, CTLA4-Ig induces long-term, donor-specific unresponsiveness.

5/7/7 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131003885 CA: 131(1)3885b JOURNAL
Immunomodulation of the CD28-B7 system: effects of inhibition of

co-stimulatory signals provided by CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

AUTHOR(S): Nishikawa, K.; Matsuo, S.

LOCATION: Division of Nephrology, The Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan, 466-8550

JOURNAL: Nephrol., Dial., Transplant. DATE: 1999 VOLUME: 14 NUMBER: Suppl. 1 PAGES: 19-21 CODEN: NDTREA ISSN: 0931-0509 LANGUAGE: English

PUBLISHER: Oxford University Press

SECTION:

CA215000 Immunochemistry

IDENTIFIERS: review CD28 B7 signaling autoimmune glomerulonephritis, CTLA 4Ig autoimmune glomerulonephritis review

DESCRIPTORS:

Kidney, disease...

autoimmune glomerulonephritis; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

Fusion proteins(chimeric proteins)...

CTLA-4Ig, fusion protein with CTLA-4 antigen and IgG; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and

CTLA-4(antigen)...

CTLA-4Ig, fusion protein with IgG and; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and response to

CD28(antigen)... CD80(antigen)... Signal transduction,biological... effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

Immunoglobulins...

G, CTLA-4Ig, fusion protein with CTLA-4 antigen 0; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and res

Basement membrane...

glomerular; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

Immune complexes...

IgG-contg.; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and inhibition of deposition of

Immunoglobulins...

to .alpha.3 chain type IV collagen; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

Collagens,biological studies...

type IV, .alpha.3 chain; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and inhibition of

Set	Items	Description
S1	138	(B7?) (20N) (SOLUBLE OR FUSION(W) PROTEIN) AND (TUMOR? OR TUM- OUR? OR CANCER? OR NEOPLAS?)
S2	75	RD S1 (unique items)
S3	382	(B7?) (20N) (SOLUBLE OR FUSION(W) PROTEIN) AND (AUTOIMMUN? OR VIVO OR TRANSPLANT? OR GRAFT?)
S4	13	S3 AND REVIEW?
S5	7	RD S4 (unique items)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

[Search for additional matches among the next 2000 terms](#)

Search Results -

Term	Documents
B7.DWPI,EPAB,JPAB,USPT,PGPB.	8654
B7S	0
METHOD.DWPI,EPAB,JPAB,USPT,PGPB.	4848553
METHODS.DWPI,EPAB,JPAB,USPT,PGPB.	1002899
INHIBIT\$	0
INHIBIT.DWPI,EPAB,JPAB,USPT,PGPB.	265581
INHIBITA.DWPI,EPAB,JPAB,USPT,PGPB.	2
INHIBITABILITIES.DWPI,EPAB,JPAB,USPT,PGPB.	1
INHIBITABILITY.DWPI,EPAB,JPAB,USPT,PGPB.	62
INHIBITABLE.DWPI,EPAB,JPAB,USPT,PGPB.	660
.....	
BLOCK\$(BLOCKS-DETAILS).USPT,PGPB,JPAB,EPAB,DWPI.	pickup term
((B7) SAME (METHOD) SAME (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR ADMINIST\$) AND (CANCER OR NEOPLASIA OR TUMOR\$ OR TUMOUR\$)).USPT,PGPB,JPAB,EPAB,DWPI.	107

[There are more results than shown above. Click here to view the entire set.](#)

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

(B7) same (method) same (inhibit\$ or
suppress\$ or block\$ or prevent\$ or
administ\$) and (cancer or neoplasia or

[Clear](#)**Search History**

Today's Date: 9/9/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	(B7) same (method) same (inhibit\$ or suppress\$ or block\$ or prevent\$ or administ\$) and (cancer or neoplasia or tumor\$ or tumour\$)	107	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI	(B7) same (method) same (inhibit\$ or suppress\$ or block\$ or prevent\$ or administ\$)	164	<u>L5</u>
USPT,PGPB	(B7) same (method).clm.	34	<u>L4</u>
USPT,PGPB	(B7).clm.	243	<u>L3</u>
USPT,PGPB	linsley-peter\$ and B7	19	<u>L2</u>
USPT,PGPB	linsley-peter\$	38	<u>L1</u>

2/7/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12203408 BIOSIS NO.: 199900498257
Immune response enhancement by in vivo administration of **B7.2Ig**, a
soluble costimulatory protein.
AUTHOR: Swiniarski Holly; Sturmhoefel Knut; Lee Kwang; Gray Gary S; Thomas
Jenifer L; Wolf Stanley F; Dorner Andrew J; O'Toole Margot(a)
AUTHOR ADDRESS: (a)Genetics Institute, One Burt Road, Andover, MA, 01810**
USA
JOURNAL: Clinical Immunology (Orlando) 92 (3):p235-245 Sept., 1999
ISSN: 1521-6616
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The identification of both class I- and class II-restricted
tumor-associated peptides recognized by T cells has led to the test
of these peptides as immunogens in experimental immunotherapy for
cancer patients. However, optimal T cell activation requires
signaling both through the T cell receptor for antigen and through
costimulatory pathways. B7.1 and B7.2 are powerful costimulatory
molecules expressed on the surface of antigen-presenting cells. Using a
mouse model, we have sought to optimize costimulatory signals during
antipeptide responses by administering a **soluble** form of **B7.2**
at the time of peptide immunization. Administration of **B7.2Ig**
fusion protein significantly enhanced T helper cell and CTL
responses. These findings suggest that **soluble** forms of human
B7.2 protein may provide a straightforward and practical method of
supplying optimal costimulation during clinical immunotherapy.